The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Adverum Biotechnologies, Inc. Common Stock 00773U108 10,998 5,068,233 SH   OTR   0 5,068,233 0
Akero Therapeutics, Inc. Common Stock 00973Y108 13,806 617,727 SH   OTR   0 617,727 0
Aligos Therapeutics, Inc. Common Stock 01626L105 35,989 2,320,381 SH   OTR   0 2,320,381 0
Aprea Therapeutics, Inc Common Stock 03836J102 6,437 1,259,662 SH   OTR   0 1,259,662 0
Clovis Oncology, Inc. Common Stock 189464100 454 101,855 SH   OTR   0 101,855 0
Crinetics Pharmaceuticals, Inc. Common Stock 22663K107 17,276 820,720 SH   OTR   0 820,720 0
CRISPR Therapeutics AG Common Shares H17182108 55,804 498,558 SH   OTR   0 498,558 0
CymaBay Therapeutics, Inc. Common Stock 23257D103 1,985 543,753 SH   OTR   0 543,753 0
Flexion Therapeutics, Inc. Common Stock 33938J106 6,100 1,000,000 SH   OTR   0 1,000,000 0
Gritstone Oncology, Inc. Common Stock 39868T105 43,264 4,005,894 SH   OTR   0 4,005,894 0
Passage Bio, Inc. Common Stock 702712100 49,399 4,959,769 SH   OTR   0 4,959,769 0